Tevogen Bio Holdings Inc. (TVGN): Nasdaq/NYSE listing notice — Tevogen Bio receives Nasdaq deficiency notices for market value requirements

Tevogen Bio Holdings Inc.

Nasdaq notified Tevogen on Apr 16, 2026 it fails $50M minimum market value for listed securities (MVLS).
Second notice on Apr 17, 2026 for failing $15M minimum market value of publicly held shares (MVPHS).
Company has 180 days to regain compliance: MVLS by Oct 13, 2026; MVPHS by Oct 14, 2026.
Compliance requires closing at or above threshold for 10 consecutive business days.
Tevogen may consider transferring to Nasdaq Capital Market but provides no assurance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Tevogen Bio Holdings Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(A), 5450(b)

Exact text from the filing

April 16, 2026, Tevogen Bio Holdings Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company no lon

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Tevogen Bio Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-018590

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.